Efficacy of Aclidinium Bromide 400 μg Twice Daily Compared With Placebo and Tiotropium in Patients With Moderate to Severe COPD

Rabe, 2007, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary, Am J Respir Crit Care Med, 176, 532, 10.1164/rccm.200703-456SO Chapman, 2006, Epidemiology and costs of chronic obstructive pulmonary disease, Eur Respir J, 27, 188, 10.1183/09031936.06.00024505 Mathers, 2006, Projections of global mortality and burden of disease from 2002 to 2030, PLoS Med, 3, e442, 10.1371/journal.pmed.0030442 Mannino, 2007, Global burden of COPD: risk factors, prevalence, and future trends, Lancet, 370, 765, 10.1016/S0140-6736(07)61380-4 Casaburi, 2002, A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease, Eur Respir J, 19, 217, 10.1183/09031936.02.00269802 Gross, 2004, Tiotropium bromide, Chest, 126, 1946, 10.1378/chest.126.6.1946 Prat, 2009, J Med Chem, 52, 5076, 10.1021/jm900132z Gavaldà, 2009, Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile, J Pharmacol Exp Ther, 331, 740, 10.1124/jpet.109.151639 Jansat, 2009, Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants, J Clin Pharmacol, 49, 1239, 10.1177/0091270009336353 Miller, 2005, Standardisation of spirometry, Eur Respir J, 26, 319, 10.1183/09031936.05.00034805 Welte, 2008, Once versus twice daily formoterol via Novolizer for patients with moderate to severe COPD—a double-blind, randomised, controlled trial, Pulm Pharmacol Ther, 21, 4, 10.1016/j.pupt.2006.09.002 2010 Lasseter, 2011, Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers, Am J Respir Crit Care Med, 183, A1615 Jones, 2011, Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease, Respir Res, 12, 55, 10.1186/1465-9921-12-55 Donohue, 2005, Minimal clinically important differences in COPD lung function, COPD, 2, 111, 10.1081/COPD-200053377 Sentellas, 2010, Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites, Eur J Pharm Sci, 39, 283, 10.1016/j.ejps.2010.01.004 Jansat, 2009, Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects, Int J Clin Pharmacol Ther, 47, 460, 10.5414/CPP47460 Schelfhout, 2010, Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study, Br J Clin Pharmacol, 69, 458, 10.1111/j.1365-2125.2010.03622.x Jones, 2011, Aclidinium bromide in patients with chronic obstructive pulmonary disease: efficacy and safety results from ATTAIN [abstract], Am J Respir Crit Care Med, 183, A6350 Kerwin, 2010, Efficacy and safety of twice-daily aclidinium bromide in patients with COPD: results from ACCORD COPD I [abstract], Chest, 138, 469A, 10.1378/chest.10344 Kerwin, 2011, Twice-daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [abstract], Am J Respir Crit Care Med, 183, A1592 Donohue, 2002, A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol, Chest, 122, 47, 10.1378/chest.122.1.47 Littner, 2000, Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 161, 1136, 10.1164/ajrccm.161.4.9903044 Partridge, 2009, Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey, Curr Med Res Opin, 25, 2043, 10.1185/03007990903103006 Kessler, 2011, Symptom variability in patients with severe COPD: a pan-European cross-sectional study, Eur Respir J, 37, 264, 10.1183/09031936.00051110